CAR7, has shown remarkable success in reversing an aggressive form of leukemia. This world-first treatment uses genetically ...
Genetix Biotherapeutics Inc. today announced real-world data from the commercial implementation of ZYNTEGLO™ and LYFGENIA™, first-in-class ex vivo gene addition therapies for the treatment of ...
Treating our first patient is a proud moment for Abeona and a testament to the tireless resolve of our team,” said Vish ...
Investor optimism has waned as final minutes from uniQure’s pre-BLA meeting with the FDA convey that data from the company’s ...
2025 FEB 06 (NewsRx) -- By a News Reporter-Staff News Editor at Gene Therapy Daily News-- Researchers detail new data in Biotechnology - Gene Therapy. According to news reporting originating in Boston ...
The CVCT Forum is an annual, invite-only workshop that aims to cultivate a multi-stakeholder exchange to enhance clinical trials, streamline regulatory approval processes, and facilitate the ...
Investor's Business Daily on MSN
UniQure plummets, again, as FDA indicates it will reject Huntington's gene therapy
UniQure stock plunged, again, Thursday after the FDA said it doesn't have enough evidence for a Huntington's approval.
Genetix Biotherapeutics Inc. today announced their participation in the American Society of Hematology’s (ASH) exclusive press program ahead of the 67th ASH annual meeting in Orlando, Florida ...
Biotechs in the charter city of Próspera aim to cure ageing, but experts question the feasibility of their goals.
The Alliance for Regenerative Medicine has voiced deep disappointment about reports that the FDA has put the director of its cell and gene therapy office on administrative leave and escorted her out ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback